A Data Mode l for Integrating GIS and BIM for Assessment a nd 3D Visualisation of Flood Damage to Building
A Data Mode l for Integrating GIS and BIM for Assessment a nd 3D Visualisation of Flood Damage to Building
复制标题
集成 GIS 和 BIM 的数据模型，用于建筑物洪水损坏的评估和 3D 可视化
DOI：
--
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
T. Ngo
中科院分区：
文献类型：
--
作者：
Sam Amirebrahimi;A. Rajabifard;P. Mendis;T. Ngo
洪水损害评估（FDA）是现代风险管理框架的关键组成部分，为决策和风险处理提供有效的基础。目前的 FDA 方法在分析中没有考虑建筑物的独特性，因此无法逐案分析，而这对于工程和设计评估等各种应用来说是必需的。这主要是由于这些方法中使用的输入数据有限。这种微观层面的 FDA 分析所需的信息一方面包括完整的建筑信息（在 BIM 中得到很好的体现），另一方面包括通常由 GIS 管理的洪水信息。虽然单独使用 BIM 和 GIS 无法满足详细 FDA 的所有信息要求，但它们的集成可以用于此目的。然而，现有的集成方法是特定于应用程序的，FDA 采用它们具有挑战性。本文提出了一种 BIM-GIS 集成方法，以支持对建筑物洪水损坏的详细评估和 3D 可视化的要求。为此，数据建模周期被用来设计一个新的数据模型作为 GML 的概要。该模型通过案例研究进行了评估，发现可以有效满足微观层面 FDA 所需的标准。
Floo d Damage Assessment (FDA) is a key component in modern risk management frameworks providing an effective basis for decision making and the treatment of the risks. Current FDA methods do not consider the distinctiveness of buildings in analysis and therefore, cannot analyse them on a case-by-case basis, which is necessary for a variety of applications like engineering and design evaluation. This is mainly due to the limited input data used in these methods. The information required for such micro-level FDA analysis includes on one hand, complete building information (well-represented in BIM) and on the other hand, flood information that is commonly managed by GIS. While the independent use of BIM and GIS cannot satisfy all the information requirements for detailed FDA, their integration can potentially be used for this purpose. However, existing integration methods are application-specific and their adoption for FDA is challenging. This paper presents a method for BIM-GIS integration to support the requirements of a detailed assessment and 3D visualisation of flood damage to buildings. The data modelling cycle was used to design a new data model as a profile of GML for this purpose. The model was evaluated using a case study and found effective to satisfy the required criteria for micro-level FDA.